Cohance Swaps Vials for Value—Sells CR Bio Unit for ₹160 Cr

Cohance Lifesciences Ltd. (COHA.NS) today announced the sale of its Clinical Research and Bio-Analytical Studies (CR Bio) segment for aggregate consideration of ₹160 crore, as part of its strategic portfolio re-balancing initiative. The transaction is expected to close during the second quarter of FY2025–26, upon satisfaction of customary closing conditions and regulatory approvals.

 

The CR Bio business unit providing bioavailability and bioequivalence (BA/BE) studies has been Cohance's clinical and analytical services business. The sale is also consistent with the company's emphasis on expanding its core CDMO (Contract Development and Manufacturing Organization) and API/formulations businesses, where it has seen momentum in growth.

 

Cohance stated that the proceeds from the sale will be used to strengthen its balance sheet, enable capacity expansion, and fuel high-margin growth acceleration. The buyer has not been identified.

 

The transaction follows a series of strategic investments made by Cohance, including international market expansion, R&D expenditure, and specialty chemical CDMO growth.

 

Deal Synopsis:

Sources: Rediff MoneyWiz, Cohance Lifesciences – Official Website, Trendlyne – Cohance Lifesciences Corporate Filings